B. Riley Securities Reiterates Buy on Starling Oncology, Lowers Price Target to $10

Benzinga · 1d ago
B. Riley Securities analyst Yuan Zhi reiterates Starling Oncology (NASDAQ:STLN) with a Buy and lowers the price target from $11 to $10.